Insider Buying: Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) CEO Acquires $24,300.00 in Stock

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) CEO Brian Culley bought 15,000 shares of the business’s stock in a transaction on Thursday, March 12th. The shares were acquired at an average price of $1.62 per share, with a total value of $24,300.00. Following the transaction, the chief executive officer directly owned 255,516 shares of the company’s stock, valued at approximately $413,935.92. This trade represents a 6.24% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Lineage Cell Therapeutics Stock Up 1.9%

LCTX opened at $1.61 on Friday. The firm has a 50-day moving average price of $1.73 and a 200-day moving average price of $1.67. Lineage Cell Therapeutics, Inc. has a twelve month low of $0.37 and a twelve month high of $2.09. The company has a market capitalization of $401.03 million, a price-to-earnings ratio of -5.75 and a beta of 1.74.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last announced its quarterly earnings results on Thursday, March 5th. The company reported $0.00 EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.07. The company had revenue of $6.61 million for the quarter, compared to analysts’ expectations of $1.96 million. Lineage Cell Therapeutics had a negative net margin of 436.47% and a negative return on equity of 76.13%. On average, sell-side analysts expect that Lineage Cell Therapeutics, Inc. will post -0.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. HC Wainwright restated a “buy” rating on shares of Lineage Cell Therapeutics in a research report on Friday, March 6th. D. Boral Capital lifted their price target on Lineage Cell Therapeutics from $2.00 to $3.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $6.00.

Institutional Trading of Lineage Cell Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC bought a new position in Lineage Cell Therapeutics in the 4th quarter valued at $25,000. Citizens Financial Group Inc. RI bought a new position in shares of Lineage Cell Therapeutics in the third quarter worth $25,000. Define Financial LLC purchased a new stake in shares of Lineage Cell Therapeutics in the fourth quarter worth $33,000. DLD Asset Management LP purchased a new stake in shares of Lineage Cell Therapeutics in the fourth quarter worth $33,000. Finally, Kestra Advisory Services LLC boosted its stake in Lineage Cell Therapeutics by 174.7% during the fourth quarter. Kestra Advisory Services LLC now owns 27,747 shares of the company’s stock valued at $46,000 after buying an additional 17,647 shares during the period. Institutional investors own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.